Status: Recruiting
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.
Participants needed: 130
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sapience TherapeuticsUpdated: May 11, 2025Locations: 11
Eligibility criteria
Able and willing to sign an informed consent form (ICF) and comply with the prot... [+4]
Agrees to provide a newly obtained biopsy of an accessible lesion (if they can b... [+17]